Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

10.60USD
4:00pm EDT
Change (% chg)

$0.20 (+1.92%)
Prev Close
$10.40
Open
$10.40
Day's High
$10.60
Day's Low
$10.32
Volume
48,328
Avg. Vol
101,560
52-wk High
$29.00
52-wk Low
$9.85

Chart for

About

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $338.08
Shares Outstanding(Mil.): 31.60
Dividend: --
Yield (%): --

Financials

  PRTK.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -3.12 -- --
ROI: -60.10 -3.67 13.17
ROE: -91.17 -5.61 15.10

BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91

* PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

BRIEF-Paratek Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* PARATEK ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

May 01 2018

BRIEF-Highbridge Capital Management Reports 6.54 Pct Passive Stake In Paratek Pharmaceuticals

* HIGHBRIDGE CAPITAL MANAGEMENT, LLC REPORTS 6.54 PERCENT PASSIVE STAKE IN PARATEK PHARMACEUTICALS INC AS OF APRIL 23, 2018 - SEC FILING Source : https://bit.ly/2HIcM0E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 30 2018

BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

Apr 19 2018

BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

Apr 18 2018

BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors

* PARATEK APPOINTS ROLF K. HOFFMAN TO COMPANY’S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 13 2018

BRIEF-Paratek's New Drug Applications For Oral And Intravenous Omadacycline Accepted For Priority Review By FDA

* PARATEK’S NEW DRUG APPLICATIONS FOR ORAL AND INTRAVENOUS OMADACYCLINE ACCEPTED FOR PRIORITY REVIEW BY FDA

Apr 04 2018

BRIEF-Paratek Pharmaceuticals Reports Q4 Loss Per Share $0.78

* PARATEK PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REMAINS ON TRACK FOR COMMERCIAL LAUNCH BY FIRST QUARTER 2019

Mar 01 2018

BRIEF-Paratek Completes Submission Of New Drug Applications To U.S.FDA

* PARATEK COMPLETES SUBMISSION OF NEW DRUG APPLICATIONS TO U.S. FOOD AND DRUG ADMINISTRATION FOR ORAL AND INTRAVENOUS OMADACYCLINE FOR PNEUMONIA AND SKIN INFECTIONS Source text for Eikon: Further company coverage:

Feb 05 2018

Earnings vs. Estimates